loader2
Partner With Us NRI

Concord Biotech Ltd share Price Today

Company details

1,441.40
1,545.90
900.05
1,725.00
6M Return 15.75%
1Y Return 62.34%
Mkt Cap.(Cr) 16,011.48
Volume 221,609
Div Yield 0.57%
OI
-
OI Chg %
-
Volume 221,609

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Concord Biotech Ltd shares SWOT Analysis

Strengths (9)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Effectively using its capital to generate profit - RoCE improving in last 2 years
  • Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Weakness (1)

  • MFs decreased their shareholding last quarter

Opportunity (3)

  • Negative to Positive growth in Sales and Profit with Strong Price momentum
  • RSI indicating price strength
  • High Volume, High Gain

Threats (2)

  • Big Deal (Insider and SAST) sells last month greater than 1% of total shares
  • High PE (PE > 40)

Resistance and support

R1 1,570.5
R2 1,610.4
R3 1,675.0
Pivot

1,505.93

S1 1,466.0
S2 1,401.4
S3 1,361.5
EMA SMA
1,467.5
1,484.0
1,453.0
1,347.0
1,454.2
1,516.3
1,481.7
1,353.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL Bulk Purchase 2024-05-28 1386.95 600000 NSE
1575773 ONTARIO INC Bulk Sell 2024-05-28 1361.26 3548211 NSE
SOCIETE GENERALE Block Purchase 2024-01-25 1421.7 153421 BSE
Name Category Shares
Sudhir Vaid PROMOTER 28.84%
Manju Vaid PROMOTER 9.55%
Ankur Sudhir Vaid PROMOTER 0.56%
Vaid Megha Ankur PROMOTER 0.52%
Sudman Consultants LLP PROMOTER 4.54%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Concord Biotech Ltd Stocks COMPARISON

Financials( in Cr) Concord Biotech Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 1,530.50 1,516.00 1,564.75 4,588.60 1,109.55
% Change 5.94 0.34 1.31 -0.11 1.75
Mcap Cr 16,011.48 363,739.19 126,332.75 121,813.11 111,646.69
Revenue TTM Cr 1,016.94 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 308.10 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 53.81 36.34 29.68 76.10 28.94
1 Year Return 62.34 53.43 59.42 31.57 114.34
ROCE 29.05 16.79 14.76 19.30 16.25
ROE 21.88 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,526.64 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 33,119.99 -408.46
LAST 3M 113,155.52 -36,230.77
LAST 6M 183,603.09 -15,050.11
LAST 12M 290,144.87 98,834.05

Concord Biotech Ltd Information

Stock PE (TTM)
53.81
Promoter Holding
44.08%
Book Value
145.9282
ROCE
29.05%
ROE
21.88%
Description
  • Concord Biotech Ltd was originally incorporated as `Servomed Pharmaceuticals Private Limited` at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to `Concord Biotech Limited` dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based biopharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immuno-suppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat. In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat. It set up a joint venture in Japan to grow business in 2018. In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market. A second API manufacturing facility at Limbasi was launched, which commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. As of March 31, 2022, the annual installed production capacity of formulation facility in Valthera amounted to 522.64 million units, with an average dosage capability of 0.17 million tablets, 0.36 million capsules and 646.46 bottles of dry syrup per shift, which is defined as eight hours of production. The Company is planning to raise capital from Public by issuing o 20,925,652 Equity Shares through Offer for Sale.

Registered Address

1482-86 Trasad Road, Dholka, Ahmedabad, Gujarat, 382225

Tel : 91-079-68138700
Email : complianceofficer:concordbiotech.com
Website : http://www.concordbiotech.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 543960
NSE Code : CONCORDBIO
Book Closure Date (Month) :
BSE Group : B
ISIN : INE338H01029

FAQ’s on Concord Biotech Ltd Shares

You can buy Concord Biotech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Concord Biotech Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:57 PM the closing price of Concord Biotech Ltd was Rs.1,530.50.

The latest PE ratio of Concord Biotech Ltd as of Jun 14, 2024 03:57 PM is 53.81

The latest PB ratio of Concord Biotech Ltd as of Jun 14, 2024 03:57 PM is 0.10

The 52-week high of Concord Biotech Ltd share price is Rs. 1,725.00 while the 52-week low is Rs. 900.05

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:57 PM, the market cap of Concord Biotech Ltd stood at Rs. 16,011.48.

Download App

Download Our App

Play Store App Store
market app